1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione
• 英文别名: 2'-epi-Sofosbuvir Desphosphate；1-[(2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidine-2,4-dione
• 化学式: C₁₀H₁₃FN₂O₅
• 分子量: 260.222
• InChiKey: ARKKGZQTGXJVKW-UZRKRJFESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 在 2,6-二甲基吡啶 、 三氯硫磷 、 奎宁 、 水 作用下， 以 四氢呋喃 为溶剂， 以56%的产率得到O-(((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl) O,O-dihydrogen phosphorothioate
  参考文献：
  名称：

  金鸡纳生物碱催化的新机制允许有效的硫代磷酸化反应

  摘要：

  使用金鸡纳生物碱催化剂，在温和的反应条件下，使用市售的硫代磷酰氯高效合成核苷 5'-单硫代磷酸酯。对该反应进行了详细的机理研究，结合了反应动力学、核磁共振光谱和计算模型，以更好地了解观察到的反应性。总的来说，结果支持此类有机催化剂的前所未有的机制。

  DOI：

  10.1021/jacs.0c09192
• 作为产物：
  描述：

  1-O-甲基-3,5-二-O-[(2,4-二氯苯基)甲基]-alpha-D-赤式戊呋喃糖苷-2-酮 在 4-二甲氨基吡啶 、 N,O-双三甲硅基乙酰胺 、 二乙胺基三氟化硫 、 三氯化硼 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 10.5h， 生成 1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  Discovery of 2′-α-C-Methyl-2′-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus

  摘要：

  2'-alpha-C-Methyl-2'-beta-C-fluorouridine and its phosphoramidate prodrugs were synthesized and evaluated for their inhibitory activity against HCV. The structure-activity relationship analysis of the phosphoramidate moiety found that 17m, 17q, and 17r exhibit potent activities against HCV, with EC50 values of 1.82 +/- 0.19, 0.88 +/- 0.12, and 2.24 +/- 0.22 mu M, respectively. The docking study revealed that the recognition of the 2'-beta-F by Arg158, 3'-OH by N291, and the Watson Crick pairing with the template allowed 23 to form the in-line conformation necessary for its incorporation into the viral RNA chain.

  DOI：

  10.1021/acsmedchemlett.6b00270

文献信息

• Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides
  申请人：Zhong Minghong

  公开号：US20150266918A1

  公开（公告）日：2015-09-24

  Provided herein are bridged cyclic phosphates and phosphoramidates (bc-ProTides) of nucleosides, which is a compound, its stereoisomers, isotope-enriched analogues, pharmaceutically acceptable salts, hydrates, solvates, or crystalline or polymorphic forms thereof, with the following structure: These compounds can be used for the treatment of viral infections and/or neoplastic diseases in mammals. By optimizing combinations of Y 2 , Y 3 , R 0 , and M, the cleavability of these compounds as prodrugs can be attuned for different tissue targeting with various functional combinations. Also disclosed are processes and methods for preparation of these compounds.

  本文提供了核苷的桥接环磷酸酯和磷酰胺酯（bc-ProTides），这是一种化合物，包括其立体异构体、同位素富集类似物、药用可接受盐、水合物、溶剂合物，或其结晶或多形式，具有以下结构： 这些化合物可用于治疗哺乳动物的病毒感染和/或肿瘤性疾病。通过优化Y 2 、Y 3 、R 0 和M的组合，这些化合物作为前药的可裂性可以调节以适应不同组织靶向和各种功能组合。还公开了制备这些化合物的过程和方法。
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF SOFOSBUVIR<br/>[FR] PROCÉDÉ AMÉLIORÉ DE SYNTHÈSE DE SOFOSBUVIR
  申请人：OPTIMUS DRUGS (P) LTD

  公开号：WO2018015821A1

  公开（公告）日：2018-01-25

  The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of Sofosbuvir. The present invention involves use of reagents that are less expensive, easier to handle and eco-friendly process.

  本发明涉及一种改进的、具有商业可行性和工业优势的索非布韦制备方法。本发明涉及使用价格较低、易于处理且环保的试剂。
• [EN] NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIVIRAUX ET ANTITUMORAUX
  申请人：UNIV LEUVEN KATH

  公开号：WO2015158913A1

  公开（公告）日：2015-10-22

  The present invention relates to novel phosphate-modified nucleosides, such as phosphoramidate nucleosides. The invention also relates to the use of these novel phosphate-modified nucleosides to treat or prevent viral infections and proliferative diseases (such as cancer) and their use to manufacture a medicine to treat or prevent viral infections and proliferative diseases particularly infections with viruses belonging to the HCV family.

  本发明涉及新型磷酸酯修饰核苷，如磷酰胺酸酯核苷。该发明还涉及利用这些新型磷酸酯修饰核苷来治疗或预防病毒感染和增殖性疾病（如癌症），以及它们用于制造用于治疗或预防病毒感染和增殖性疾病，特别是感染HCV家族病毒的药物。
• [EN] NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES RENFERMANT DES NUCLÉOTIDES ET DES NUCLÉOSIDES ET UTILISATIONS ASSOCIÉES
  申请人：UNIV EMORY

  公开号：WO2014124430A1

  公开（公告）日：2014-08-14

  This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to halogenated nucleosides optionally conjugated to a phosphorus oxide or pharmaceutically acceptable salts thereof. In certain embodiments, the disclosure relates to conjugate compounds or pharmaceutically acceptable salts thereof comprising an amino acid ester or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.

  这项披露涉及核苷酸和核苷类治疗组合物及其相关用途。在某些实施例中，该披露涉及卤代核苷，可选择地与磷氧化物或其药用可接受盐结合。在某些实施例中，该披露涉及结合物或其药用可接受盐，包括通过磷氧化物与核苷酸或核苷相连的氨基酸酯或鞘脂类或衍生物。在某些实施例中，该披露考虑了包括这些化合物的药用组合物，用于治疗传染病、病毒感染和癌症。
• [EN] N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION<br/>[FR] ESTER DE N-[(2 ' R) -2' -DÉSOXY-2' -FLUORO-2' -MÉTHYL-P-PHÉNYL-5' -URIDYLYL]-L-ALANINE 1-MÉTHYLÉTHYLE ET SON PROCÉDÉ DE PRODUCTION
  申请人：PHARMASSET INC

  公开号：WO2010135569A1

  公开（公告）日：2010-11-25

  Disclosed herein are nucleoside phosphoramidates of formula 4 and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. Disclosed is also a process for preparing compound represented by formula 4: (Formula 4) wherein P* represents a chiral phosphorus atom, which comprises: a) reacting an isopropyl-alanate, (Formula A), a di-X'-phenylphosphate, (Formula B), 2'-deoxy-2f-fluoro-2'-C-methyluridine, (Formula 3), and a base to obtain a first mixture comprising 4; wherein X is a conjugate base of an acid, n is 0 or 1, and X' is a halogen, b) reacting the first mixture with a protecting compound to obtain a second mixture comprising 4; and c) optionally subjecting the second mixture to crystallization, chromatography or extraction in order to obtain 4.

  本文披露了化学式4的核苷酸磷酰胺及其作为治疗病毒性疾病的药物的用途。这些化合物是RNA依赖性5RNA病毒复制的抑制剂，可作为HCV NS5B聚合酶的抑制剂，HCV复制的抑制剂以及哺乳动物丙型肝炎感染的治疗药物。还披露了一种制备化合物4的方法：（化学式4），其中P*代表手性磷原子，包括：a）反应异丙基-丙氨酸酯（化学式A）、二-X'-苯基磷酸酯（化学式B）、2'-脱氧-2f-氟-2'-C-甲基尿嘧啶（化学式3）和碱以获得含有4的第一混合物；其中X是酸的共轭碱基，n为0或1，X'是卤素；b）将第一混合物与保护化合物反应以获得含有4的第二混合物；c）可选地将第二混合物经结晶、色谱或萃取处理以获得4。